查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001074

MRI造影剂市场：产品类型、给药途径、通路、应用、最终用途－2026-2032年全球市场预测

MRI Contrast Media Agents Market by Product Type, Administration Route, Distribution Channel, Application, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，MRI造影剂市场价值将达到 28.8 亿美元，到 2026 年将成长至 31.1 亿美元，到 2032 年将达到 49.9 亿美元，复合年增长率为 8.15%。

主要市场统计数据
基准年 2025 28.8亿美元
预计年份：2026年 31.1亿美元
预测年份 2032 49.9亿美元
复合年增长率 (%) 8.15%

对 MRI造影剂进行了权威概述，涵盖了影响产品开发和临床应用的化学多样性、临床效用和安全要求。

磁振造影（MRI）造影剂是现代诊断成像的关键，能够提高组织对比度，并在广泛的临床适应症中实现可靠的成像。该领域化学成分多样，不仅包括历史上在许多诊断流程中占据主导地位的钆基造影剂，还包括旨在满足特定安全性和诊断目标的铁基和锰基替代造影剂。除了化学性质外，製剂特性（例如离子或非离子性质）和分子结构（特别是钆错合中线性螯合物和大环螯合物结构之间的差异）也会影响临床性能和安全性。

安全审查、影像技术的进步以及法规环境的重组如何推动 MRI造影剂创新和应用方面的策略转型。

由于多种因素的共同作用，包括加强安全监测、影像通讯协定进步以及监管和采购环境的重组，磁振造影（MRI）造影剂领域正经历变革性的转变。安全性问题，特别是与钆在体内滞留相关的问题，加速了人们对大环螯合剂的关注。与线性螯合剂相比，大环螯合剂具有更高的动力学稳定性，并且正在成为许多临床路径中的首选。同时，创新已从钆扩展到铁基和锰基造影剂，旨在平衡诊断性能与差异化的安全性和药物动力学特性。

到 2025 年，累积关税将导致供应链重组和策略性製造决策，从而重塑整个 MRI造影剂生态系统，包括采购、购买和业务永续营运。

2025年累积关税的实施，导致MRI造影剂生产商、经销商和医疗服务提供者的供应链经济和策略规划发生重大调整。为此，各机构被迫重新审视其原料药、螯合剂和成品的筹资策略，尤其关注原料供应商和契约製造的地理分布。这种调整更强调供应的稳定性和韧性，促使供应商网路多元化，并转向紧急库存策略，以应对进口成本波动和运输中断。

清晰的细分市场分析揭示了产品化学特性、临床应用、最终使用环境、分销管道和给药途径如何共同决定策略重点。

详细的細項分析阐明了产品特性、临床应用案例和通路之间的相互作用，从而确定了策略重点和商业化策略。根据产品类型，产品组合通常分为离子型和非离子型製剂。离子型产品主要包括钆基药物，这些药物可进一步分为线性药物和大环药物，因为分子结构会显着影响其在体内的稳定性和安全性。非离子型产品线涵盖更广泛的化学成分，包括钆基、铁基和锰基药物，其中非离子型钆类药物还可根据其分子结构（如适用）进一步分为线性结构和大环结构。

美洲、欧洲、中东和非洲以及亚太地区的区域监管、临床和供应方面的考量决定了招募模式和策略定位。

区域趋势是产品策略、监管规划和商业性实施的核心决定因素，并且在美洲、欧洲、中东和非洲以及亚太等主要市场之间存在差异。在美洲，临床网路和采购集团通常优先考虑循证应用和大规模采购合同，这促使製造商优先考虑可靠的安全资料集和高效的物流系统，以支援国家和地区医院系统。美国的法规环境和该地区的报销结构影响着定价和打入市场策略，而北美学术机构经常主导临床研究，为全球指南的製定做出贡献。

在 MRI造影剂市场中，成熟的製药公司和专业研发公司如何透过建立证据、整合供应链和伙伴关係来维持竞争优势？

磁振造影造影剂领域的竞争格局由成熟的製药和医学影像公司以及敏捷的专业研发公司共同塑造，这些公司致力于开发新型化学结构和标靶製剂。成熟公司专注于优化产品组合、累积安全性证据，并在生产和分销方面实现规模经济。这些公司通常会投资于製剂改进、拓展新的适应症以及进行标靶临床试验，以保护和重新定位其现有产品，因为客户维繫风险和螯合物稳定性问题日益凸显。同时，中小型生物技术公司和专业製药公司正在开发具有独特安全性和成像功能特性的铁基和锰基造影剂，并积极寻求合作和许可，以实现实际的商业化。

为产业领导者提供切实可行的策略，以确保供应、加强安全证据并加快临床部署，同时降低关税和监管风险。

领导企业若想在磁振造影造影剂领域维持并扩大领先地位，应采取一系列切实可行的策略，优先考虑安全性、供应链韧性和实证商业化。首先，企业应优先投资于具有成熟稳定性和安全性的分子设计和配方，同时积极收集必要的临床数据，以支持差异化标籤并增强临床医生的信心。其次，企业应实现采购和製造地的多元化，以降低关税波动和物流中断的影响。这包括考虑关键原材料的近岸外包和合格的双重采购。

采用严谨的混合方法研究途径，结合临床医师的访谈、监管审查和证据的三角检验，得出可操作的策略见解。

本分析所依据的研究结合了与该领域专家进行的初步定性研究、对监管和临床文献的全面回顾，以及与公开的临床试验註册资讯和专利申请资讯的三角验证。主要资讯来源包括对临床放射科医生、药物安全监测专家、医院采购经理以及研发主管的结构化检验，旨在收集关于临床需求、推广障碍和供应链优先事项的第一手观点。二级资讯来源包括监管公告、同行评审的安全性和有效性研究以及与螯合化学和製剂方法相关的技术文件。

整合临床、营运和政策要求，制定策略路径，打造具有韧性且以患者为中心的 MRI造影剂产品组合。

总之，磁振造影造影剂市场环境正处于转折点，安全需求、技术进步和外部政策趋势正在塑造短期和中期策略。相关人员必须权衡钆基造影剂已确立的诊断效用与解决其在体内持久性问题的必要性，优先发展大环化学，并在临床适用的情况下促进非钆基替代品的开发。同时，贸易政策变化带来的营运和商业性影响，也要求重新关注供应链多元化和生产柔软性，以确保患者照护的连续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：MRI造影剂市场：依产品类型划分

  • 离子
  • 非离子型
    • 钆基造影剂
      • 线性造影剂
      • 大环造影剂
    • 铁基造影剂
    • 锰基造影剂

第九章：依给药途径分類的MRI造影剂市场

  • 关节内给药
  • 静脉注射
  • 口服

第十章：MRI造影剂市场：依通路划分

  • 直销
  • 医院药房
  • 网路药房
  • 零售药房

第十一章 MRI造影剂市场：依应用领域划分

  • 腹部影像
    • 消化系统成像
    • 肝臟影像诊断
  • 心血管影像
    • 心臟影像
    • 血管影像
  • 中枢神经系统影像
  • 肌肉骨骼影像诊断

第十二章 MRI造影剂市场：依最终用途划分

  • 门诊手术中心
  • 诊断影像中心
  • 医院
    • 当地医院
    • 三级医疗医院
  • 研究机构

第十三章 MRI造影剂市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 MRI造影剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 MRI造影剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核磁共振造影剂市场

第十七章：中国磁振造影造影剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer AG
  • Beijing Beilu Pharmaceutical Co., Ltd.
  • Bracco Imaging SpA
  • Curium Pharma
  • Daiichi Sankyo Company, Limited
  • Fresenius Kabi AG
  • FUJIFILM Corporation
  • GE HealthCare
  • Guerbet Group
  • JB Chemicals & Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lantheus Medical Imaging, Inc.
  • Livealth Biopharma Pvt. Ltd.
  • Miltenyi Biotec BV & Co. KG
  • NTI Ltd.
  • Spago Nanomedical AB
  • Taejoon Pharm Co., Ltd.
  • Vitalquan, LLC
Product Code: MRR-F927BA46208C

The MRI Contrast Media Agents Market was valued at USD 2.88 billion in 2025 and is projected to grow to USD 3.11 billion in 2026, with a CAGR of 8.15%, reaching USD 4.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.88 billion
Estimated Year [2026] USD 3.11 billion
Forecast Year [2032] USD 4.99 billion
CAGR (%) 8.15%

An authoritative orientation to MRI contrast media agents that frames chemical diversity, clinical utility, and safety imperatives shaping product development and clinical adoption

Magnetic resonance imaging contrast media agents are integral to modern diagnostic imaging, enhancing tissue contrast and enabling confident interpretation across a broad range of clinical indications. The landscape is chemically diverse, encompassing gadolinium-based agents historically dominant in many diagnostic workflows, alongside iron- and manganese-based alternatives engineered to address specific safety and imaging objectives. Beyond chemistry, formulation attributes such as ionic versus non-ionic character and molecular architecture-specifically linear versus macrocyclic chelation for gadolinium complexes-inform both clinical performance and safety profiles.

Clinical utility spans abdominal, cardiovascular, central nervous system, and musculoskeletal imaging, and these applications drive nuanced requirements for relaxivity, biodistribution, and clearance. Consequently, stakeholders must weigh diagnostic benefits against evolving safety evidence and regulatory guidance. Over recent years, concerns regarding gadolinium retention in tissues and the risk, albeit low, of nephrogenic systemic fibrosis in susceptible patients have catalyzed both innovation and reappraisal of prescribing patterns. Therefore, a contemporary introduction to contrast media must foreground not only pharmacological and physicochemical attributes, but also emerging clinical best practices, risk mitigation measures, and the regulatory environment shaping product availability and labeling.

This orientation sets the stage for strategic analysis: manufacturers, clinicians, and procurement leaders benefit from a clear understanding of how molecular design, administration route, and end-use setting converge to determine clinical adoption, safety monitoring, and commercial viability. As the diagnostic imaging ecosystem evolves, this foundational perspective enables stakeholders to anticipate shifts in product preference, investment priorities, and collaborative pathways across industry and healthcare delivery systems.

How safety scrutiny, imaging technology advances, and regulatory realignment are catalyzing a strategic transformation across MRI contrast agent innovation and adoption

The landscape for MRI contrast agents is undergoing transformative shifts driven by converging forces: heightened safety scrutiny, technological advances in imaging protocols, and a reconfigured regulatory and procurement environment. Safety concerns, particularly those related to gadolinium retention, have accelerated interest in macrocyclic chelates, which offer greater kinetic stability than linear counterparts and are increasingly positioned as preferred options in many clinical pathways. Meanwhile, innovation is expanding beyond gadolinium into iron- and manganese-based agents that aim to balance diagnostic performance with differentiated safety and pharmacokinetic properties.

Concurrently, improvements in MRI hardware and sequence design are altering contrast requirements; higher-field scanners, quantitative imaging biomarkers, and AI-enhanced post-processing can increase sensitivity and may reduce the reliance on high-dose contrast administrations. These technological advances encourage manufacturers and clinical teams to re-evaluate dosing strategies and to develop agents optimized for specific imaging paradigms. Regulatory agencies are responding with more granular guidance on labeling, risk communication, and post-market surveillance, prompting manufacturers to invest in longitudinal safety studies and to strengthen pharmacovigilance infrastructures.

From a commercial perspective, these shifts are prompting strategic realignments across the value chain. Organizations are prioritizing portfolio rationalization to emphasize safer, higher-evidence products, forging cross-sector partnerships to accelerate development of non-gadolinium agents, and enhancing engagement with radiology networks to support evidence generation and adoption. As a result, the sector is transitioning from a legacy, commodity-driven model toward a differentiated, evidence-led ecosystem in which safety, clinical outcomes, and operational integration determine long-term competitive advantage.

Cumulative tariff-driven supply chain recalibrations and strategic manufacturing decisions reshaping sourcing, procurement, and operational resilience across the MRI contrast ecosystem in 2025

The introduction of cumulative tariffs in 2025 has produced a material recalibration of supply chain economics and strategic planning across manufacturers, distributors, and healthcare providers dealing with MRI contrast agents. In response, organizations have had to re-examine sourcing strategies for APIs, chelating agents, and finished formulations, with particular attention to the geographic footprint of raw material suppliers and contract manufacturers. This recalibration has increased the emphasis on supply security and resilience, prompting a shift toward diversified supplier networks and contingency inventory strategies to buffer against import cost volatility and transport disruptions.

Furthermore, the tariff environment has influenced decisions about inward investment and the localization of manufacturing capacity. Some companies are evaluating the benefits of onshore or nearshore production to reduce exposure to import duties and to shorten lead times for hospital procurement cycles. These considerations interact with regulatory timelines and quality requirements, as establishing domestic manufacturing necessitates compliance with regional regulatory frameworks and validation of manufacturing processes. From a procurement perspective, hospitals and imaging centers are renegotiating contracts and seeking pricing mechanisms that mitigate tariff-driven cost exposure, while distributors are adjusting commercial models to reflect increased landed costs and to protect margin structures.

In addition, the tariff context has amplified interest in formulations and administration strategies that reduce per-patient product consumption, including optimizing dosage protocols and supporting alternatives that offer comparable diagnostic value at lower administered mass. Finally, this period has underscored the importance of policy engagement: industry players are intensifying dialogues with trade and health authorities to clarify tariff classifications, pursue exemptions where justified for critical clinical supplies, and advocate for predictable trade policies that support uninterrupted patient care and continued innovation.

Segment-based clarity revealing how product chemistry, clinical applications, end-use settings, distribution channels, and administration routes converge to drive strategic priorities

A granular view of segmentation clarifies how product features, clinical use cases, and distribution pathways interact to define strategic priorities and commercialization tactics. Based on product type, portfolios are commonly divided into ionic and non-ionic formulations. Ionic products predominantly include gadolinium-based agents, and within that category a further distinction is drawn between linear agents and macrocyclic agents because molecular architecture significantly influences in-vivo stability and safety perceptions. Non-ionic product lines encompass a broader chemistry set that includes gadolinium-based agents, iron-based agents, and manganese-based agents, with gadolinium within the non-ionic subset also categorized by linear and macrocyclic structure when applicable.

Based on agent class, the field is organized into gadolinium-based, iron-based, and manganese-based agents, where gadolinium options are again differentiated into linear and macrocyclic forms to reflect differences in chelation stability. Based on application, contrast agents are applied across abdominal imaging, cardiovascular imaging, central nervous system imaging, and musculoskeletal imaging; abdominal imaging itself is subdivided into gastrointestinal and liver imaging while cardiovascular imaging can be decomposed into cardiac and vascular imaging to align with distinct diagnostic protocols and dosing considerations.

Based on end use, the agents are deployed in settings ranging from ambulatory surgical centers and diagnostic imaging centers to hospitals and research institutes, with hospitals further classified into community hospitals and tertiary care centers to reflect variation in case complexity and purchasing behavior. Based on distribution channel, the market engages direct sales to institutional customers as well as hospital pharmacies, online pharmacies, and retail pharmacy channels that serve outpatient demand. Finally, based on administration route, agents are employed through intraarticular, intravenous, and oral administration pathways, each of which presents different formulation, delivery device, and clinical workflow requirements that manufacturers must address in product design and commercialization planning.

Region-specific regulatory, clinical, and supply considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption patterns and strategic positioning

Regional dynamics are a central determinant of product strategy, regulatory planning, and commercial execution, and they vary across major markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical networks and purchasing aggregates often emphasize evidence-led adoption and large-scale procurement agreements, which influence manufacturers to prioritize robust safety dossiers and streamlined logistics to support national and regional hospital systems. The United States regulatory environment and reimbursement structures in the region shape pricing and market entry strategies, while North American academic centers frequently lead clinical research that informs global guidelines.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and clinical practices where pan-regional harmonization efforts coexist with country-level variation. European regulatory authorities have been active on safety communication and post-market surveillance, prompting manufacturers to tailor pharmacovigilance and labeling across jurisdictions. In the Middle East and Africa, infrastructure constraints and regional procurement models create different adoption timelines, and stakeholders may prioritize cost-effective formulations and logistical simplicity when implementing contrast-enhanced imaging programs.

Asia-Pacific is characterized by rapid capacity expansion, diverse regulatory maturity, and strong manufacturing ecosystems for both API and finished products. Several markets in the region combine large patient volumes with growing diagnostic capabilities, encouraging local manufacturers and global companies to form partnerships and to invest in regional clinical evidence generation. Across these regions, strategic differentiation rests on aligning product attributes with local clinical practice, regulatory expectations, and distribution realities to optimize adoption and sustain supply continuity.

How incumbent pharmaceutical and specialty developers are pursuing evidence, supply integration, and partnerships to sustain competitive advantage in MRI contrast media

Competitive dynamics in the MRI contrast agent space are shaped by incumbent pharmaceutical and medical imaging companies, alongside nimble specialty developers advancing novel chemistries and targeted formulations. Established players focus on portfolio optimization, safety evidence generation, and scale efficiencies in manufacturing and distribution. These companies often invest in reformulations, new labeling claims, and targeted clinical studies to defend and reposition legacy products in a market increasingly attentive to retention risk and chelate stability. At the same time, smaller biotechnology firms and specialty pharmaceutical companies are advancing iron- and manganese-based agents that offer differentiated safety or functional imaging properties, driving partnerships and licensing activity as a pragmatic route to commercialization.

Strategic behaviors include vertical integration of supply chains to secure critical raw materials, collaboration with imaging device manufacturers to demonstrate product-device synergies, and selective geographic expansion guided by regulatory and clinical research priorities. In addition, there is an increasing focus on real-world evidence generation and health economics research to articulate value propositions for hospital procurement committees and payers. Distribution partners and specialty pharmacies are adapting commercial models to support complex logistics for contrast media that require cold chain management, controlled inventory oversight, and alignment with hospital formularies.

Taken together, these dynamics suggest that competitive advantage will accrue to organizations that can marry high-quality safety and efficacy evidence with reliable, flexible supply capabilities, and that can translate clinical differentiation into operational and economic benefits for healthcare providers.

Practical strategic actions for industry leaders to secure supply, strengthen safety evidence, and accelerate clinical adoption while mitigating tariff and regulatory risks

Leaders seeking to preserve and expand their position in the MRI contrast media domain should adopt a set of actionable strategies that emphasize safety, supply-chain resilience, and evidence-driven commercialization. First, prioritize investment in molecular designs and formulations with demonstrable stability and safety profiles, while advancing the clinical data necessary to support differentiated labeling and clinician confidence. Second, diversify procurement and manufacturing footprints to reduce exposure to tariff fluctuations and logistic disruptions, including evaluating nearshoring or qualified dual-sourcing for critical inputs.

Third, accelerate clinical and real-world evidence programs that directly address clinician concerns about retention and adverse events, and align these programs with regulatory reporting requirements to build trust with governing agencies. Fourth, develop commercial models that integrate with hospital formularies and imaging workflows, offering education, protocol optimization, and economic analyses to support adoption. Fifth, pursue strategic collaborations with imaging device manufacturers, academic research centers, and contract research organizations to expedite validation of agent-device synergies and to expand indications where appropriate. Finally, refine distribution strategies by blending direct sales to large institutional customers with pharmacy channel partnerships to reach outpatient markets, while ensuring rigorous cold chain and inventory controls.

By implementing these interlocking initiatives, organizations can reduce operational risk, strengthen clinical credibility, and create differentiated value propositions that resonate with radiologists, procurement leaders, and institutional payers.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, and evidence triangulation to yield actionable strategic insight

The research underpinning this analysis combined primary qualitative engagement with domain experts, comprehensive review of regulatory and clinical literature, and triangulation against public clinical trial registries and patent filings. Primary inputs included structured interviews with practicing radiologists, pharmacovigilance specialists, hospital procurement leaders, and R&D executives to capture firsthand perspectives on clinical needs, adoption barriers, and supply chain priorities. Secondary sources encompassed regulatory communications, peer-reviewed safety and efficacy studies, and technical documentation relating to chelation chemistry and formulation approaches.

Methodologically, findings were synthesized through a layered approach: clinical insights were cross-referenced with regulatory trends to assess likely labeling and surveillance implications; manufacturing and distribution considerations were modeled qualitatively to identify resilience levers under tariff pressures; and competitive strategies were validated through analysis of corporate disclosures and partnership announcements. Emphasis was placed on extracting actionable implications rather than quantitative market sizing, and all conclusions were tested for plausibility against multiple independent sources to ensure robustness and relevance for decision-makers.

Synthesis of clinical, operational, and policy imperatives that define strategic pathways for resilient and patient-centric MRI contrast media portfolios

In conclusion, the MRI contrast media landscape is at an inflection point in which safety imperatives, technological advances, and external policy dynamics collectively shape near- and medium-term strategy. Stakeholders must balance the established diagnostic utility of gadolinium-based agents with the need to respond to retention concerns by prioritizing macrocyclic chemistries and advancing non-gadolinium alternatives where clinically appropriate. At the same time, the operational and commercial impacts of trade policy shifts necessitate a renewed focus on supply chain diversification and manufacturing flexibility to maintain uninterrupted patient care.

Looking ahead, organizations that invest in high-quality clinical evidence, engage proactively with regulators, and construct resilient distribution and production architectures will be better positioned to navigate evolving clinical preferences and procurement pressures. Collaboration across the value chain-including partnerships between specialty developers, established suppliers, imaging device firms, and healthcare providers-will accelerate the development and adoption of safer, more effective contrast solutions. Ultimately, strategic success will depend on integrating scientific rigor with operational adaptability to meet the diagnostic needs of clinicians while protecting patients and sustaining long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Contrast Media Agents Market, by Product Type

  • 8.1. Ionic
  • 8.2. Non Ionic
    • 8.2.1. Gadolinium Based Agents
      • 8.2.1.1. Linear Agents
      • 8.2.1.2. Macrocyclic Agents
    • 8.2.2. Iron Based Agents
    • 8.2.3. Manganese Based Agents

9. MRI Contrast Media Agents Market, by Administration Route

  • 9.1. Intraarticular Administration
  • 9.2. Intravenous Administration
  • 9.3. Oral Administration

10. MRI Contrast Media Agents Market, by Distribution Channel

  • 10.1. Direct Sales
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. MRI Contrast Media Agents Market, by Application

  • 11.1. Abdominal Imaging
    • 11.1.1. Gastrointestinal Imaging
    • 11.1.2. Liver Imaging
  • 11.2. Cardiovascular Imaging
    • 11.2.1. Cardiac Imaging
    • 11.2.2. Vascular Imaging
  • 11.3. Central Nervous System Imaging
  • 11.4. Musculoskeletal Imaging

12. MRI Contrast Media Agents Market, by End Use

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals
    • 12.3.1. Community Hospitals
    • 12.3.2. Tertiary Care Hospitals
  • 12.4. Research Institutes

13. MRI Contrast Media Agents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. MRI Contrast Media Agents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. MRI Contrast Media Agents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States MRI Contrast Media Agents Market

17. China MRI Contrast Media Agents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Beijing Beilu Pharmaceutical Co., Ltd.
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. Curium Pharma
  • 18.9. Daiichi Sankyo Company, Limited
  • 18.10. Fresenius Kabi AG
  • 18.11. FUJIFILM Corporation
  • 18.12. GE HealthCare
  • 18.13. Guerbet Group
  • 18.14. J.B. Chemicals & Pharmaceuticals Ltd.
  • 18.15. Jiangsu Hengrui Medicine Co., Ltd.
  • 18.16. Lantheus Medical Imaging, Inc.
  • 18.17. Livealth Biopharma Pvt. Ltd.
  • 18.18. Miltenyi Biotec B.V. & Co. KG
  • 18.19. NTI Ltd.
  • 18.20. Spago Nanomedical AB
  • 18.21. Taejoon Pharm Co., Ltd.
  • 18.22. Vitalquan, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)